<DOC>
	<DOCNO>NCT00083525</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , maximum tolerate dose ( MTD ) , pharmacokinetics , pharmacodynamics combination WX-UK1 capecitabine patient advanced malignancy .</brief_summary>
	<brief_title>Urokinase-Plasminogen Activator ( uPA ) Inhibitor WX-UK1 Combination With Capecitabine Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis nonhematologic malignancy either unresponsive currently available therapy know effective therapy . Patient willing give inform consent , understand comply study procedures/restrictions Age &gt; =18 Patients must ECOG performance status 0 , 1 , 2 Life expectancy &gt; 12 week Negative serum pregnancy test woman childbearing potential nursing . Fertile patient must use effective contraception 30 day ( woman ) 4 month ( men ) treatment WXUK1 . Measurable nonmeasurable disease . Patients without clinical radiologic evidence disease eligible . Laboratory parameter ( obtain within screen period ) : WBC &gt; = 3 G/L , neutrophils &gt; = 1.5 G/L , platelets &gt; = 100 G/L , Hgb &gt; = 9 g/dL ) , total bilirubin &lt; = 1.5 x ULN , ASAT/ALAT/AP/GGT &lt; = 2.5 x ULN , serum creatinine &lt; = 2 x ULN . History hypersensitivity study drug chemically related compound excipients History current neurological disorder , particular active treat seizure disorder Known standard therapy patient 's disease potentially curative know extend life expectancy . Carcinomatous meningitis untreated/uncontrolled metastatic brain parenchymal disease . Concurrent prior ( within 4 week prior start WXUK1 treatment cytotoxic chemotherapy , biological , endocrine , investigational radiotherapy 6 week nitrosoureas , mitomycinC ) Uncontrolled infection Significant cardiac disease ( NYHA classification III IV Contraindication infusion volume 1000 ml 2 h History current blood coagulation disorder History current bleeding disorder ( include cerebral bleeding , recurrent massive nose bleeds , hematuria unexplained bruise ) Diabetes mellitus , control insulin , oral antidiabetic agent diet alone Anticoagulant thrombolytic therapy within four week prior start treatment ( except heparin flush keep port open coumadin 1 mg/day ASA 100mg/d ) Active serious illness render patient unsuitable study entry multiple blood sample Illness condition might alter absorption , distribution , metabolism elimination WXUK1 Known Hepatitis B/C HIV infection Contraindication capecitabine intake specify SPC DPDdeficiency concomitant intake sorivudine sorivudine related compound Known hemorrhagic brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>